BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 30802706)

  • 1. The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma.
    Winer LK; Dhar VK; Wima K; Morris MC; Lee TC; Shah SA; Ahmad SA; Patel SH
    J Surg Res; 2019 Jul; 239():60-66. PubMed ID: 30802706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis.
    van Erning FN; Mackay TM; van der Geest LGM; Groot Koerkamp B; van Laarhoven HWM; Bonsing BA; Wilmink JW; van Santvoort HC; de Vos-Geelen J; van Eijck CHJ; Busch OR; Lemmens VE; Besselink MG;
    Acta Oncol; 2018 Dec; 57(12):1655-1662. PubMed ID: 30264642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma.
    Ruess DA; Makowiec F; Chikhladze S; Sick O; Riediger H; Hopt UT; Wittel UA
    BMC Surg; 2015 Nov; 15():123. PubMed ID: 26615588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic adenocarcinoma: quantitative CT features are correlated with fibrous stromal fraction and help predict outcome after resection.
    Cai X; Gao F; Qi Y; Lan G; Zhang X; Ji R; Xu Y; Liu C; Shi Y
    Eur Radiol; 2020 Sep; 30(9):5158-5169. PubMed ID: 32346792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.
    Serrano PE; Cleary SP; Dhani N; Kim PT; Greig PD; Leung K; Moulton CA; Gallinger S; Wei AC
    Ann Surg Oncol; 2015 Apr; 22(4):1160-7. PubMed ID: 25348784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma.
    Malleo G; Maggino L; Ferrone CR; Marchegiani G; Luchini C; Mino-Kenudson M; Paiella S; Qadan M; Scarpa A; Lillemoe KD; Bassi C; Fernàndez-Del Castillo C; Salvia R
    Ann Surg Oncol; 2020 Oct; 27(10):3898-3912. PubMed ID: 32307617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diversity between curatively resected pancreatic head and body-tail cancers based on the 8th edition of AJCC staging system: a multicenter cohort study.
    Sheng W; Dong M; Wang G; Shi X; Gao W; Wang K; Song H; Shi G; Tan X
    BMC Cancer; 2019 Oct; 19(1):981. PubMed ID: 31640615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central pancreatectomy for early-stage pancreatic ductal adenocarcinoma: a single-center case-control study.
    Gao H; Liu T; Wang G; Gao Y; Yin L; Peng Y; Lyu N; Zhang K; Gao W; Wu J; Jiang K; Wei J; Miao Y
    Langenbecks Arch Surg; 2019 Mar; 404(2):175-182. PubMed ID: 30826926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma.
    Hu D; Ansari D; Zhou Q; Sasor A; Said Hilmersson K; Andersson R
    World J Surg Oncol; 2019 Feb; 17(1):29. PubMed ID: 30736807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative outcomes of adenosquamous carcinoma of the pancreas: An analysis of the National Cancer Database.
    Hester CA; Augustine MM; Choti MA; Mansour JC; Minter RM; Polanco PM; Porembka MR; Wang SC; Yopp AC
    J Surg Oncol; 2018 Jul; 118(1):21-30. PubMed ID: 29878370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
    Konstantinidis IT; Warshaw AL; Allen JN; Blaszkowsky LS; Castillo CF; Deshpande V; Hong TS; Kwak EL; Lauwers GY; Ryan DP; Wargo JA; Lillemoe KD; Ferrone CR
    Ann Surg; 2013 Apr; 257(4):731-6. PubMed ID: 22968073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC).
    Lianyuan T; Dianrong X; Chunhui Y; Zhaolai M; Bin J
    Cancer Biol Ther; 2018 Apr; 19(4):296-305. PubMed ID: 29313457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma.
    Nishio K; Kimura K; Amano R; Nakata B; Yamazoe S; Ohira G; Miura K; Kametani N; Tanaka H; Muguruma K; Hirakawa K; Ohira M
    World J Gastroenterol; 2017 Aug; 23(31):5764-5772. PubMed ID: 28883702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-grade pancreatic intraepithelial lesions: prevalence and implications in pancreatic neoplasia.
    Park JR; Li F; Oza VM; Sklaw BC; Cronley KM; Wellner M; Swanson B; Krishna SG
    Hepatobiliary Pancreat Dis Int; 2017 Apr; 16(2):202-208. PubMed ID: 28381386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma.
    Li G; Chen JZ; Chen S; Lin SZ; Pan W; Meng ZW; Cai XR; Chen YL
    Cancer Med; 2020 May; 9(10):3353-3370. PubMed ID: 32181599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection].
    Ridwelski K; Meyer F; Schmidt U; Lippert H
    Zentralbl Chir; 2005 Aug; 130(4):353-61. PubMed ID: 16103961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Surgical therapy of pancreatic cancer - 5 years survival].
    Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R
    Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
    Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
    Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.